Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Published byEunice Freeman Modified over 9 years ago

Similar presentations

Presentation on theme: "The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative."— Presentation transcript:

1 The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: http://www.nejm.org. End pointActive therapy PlaceboRelative risk (95% CI) p Primary outcome (death from CV causes, MI, and stroke), n (%) 519 (18.8) 547 (19.8) 0.95 (0.84-1.07) 0.41 HOPE-2: Primary outcome events with folic acid, vitamin B 6 and B 12 supplementation vs placebo at five years

2 OutcomeActive treatment PlaceboRelative risk (95% CI) Death from CV causes, n (%) 276 (10.0)291 (10.5) 0.96 (0.81-1.13) MI, n (%)341 (12.4)349 (12.6) 0.98 (0.85-1.14) Stroke, n (%)111 (4.0)147 (5.3) 0.75 (0.59-0.97) Hospitalization for unstable angina, n (%) 268 (9.7)219 (7.9) 1.24 (1.04-1.49) HOPE-2: Secondary outcomes The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: http://www.nejm.org.

3 Bønaa KH et al. N Engl J Med 2006; available at: http://www.nejm.org. GroupRate ratio 95% CIp Folic acid and B 12 vs no folic acid and B 12 1.08(0.93-1.25)0.31 B 6 vs no B 6 1.14(0.98-1.32)0.09 Folic acid, B 12, and B 6 vs placebo 1.22(1.00-1.50)0.05 NORVIT: Primary end point

Download ppt "The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative."

Similar presentations

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Cholesterol quintile (mg/dL)

Cholesterol quintile (mg/dL)
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
1 Therapies Not Indicated Andrew P. DeFilippis, Ty J. Gluckman, James Mudd, Catherine Campbell, Gregg Fonarow & Roger S. Blumenthal.

1 Therapies Not Indicated Andrew P. DeFilippis, Ty J. Gluckman, James Mudd, Catherine Campbell, Gregg Fonarow & Roger S. Blumenthal.
Randomized, double-blind, multicenter, controlled trial.

Randomized, double-blind, multicenter, controlled trial.
Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents
VBWG HPS. Lancet. 2003;361:2005-16. Gæde P et al. N Engl J Med. 2003;348:383-93. Recent statin trials: Reduction in primary outcome in patients with diabetes.

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.

RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
VBWG HOPE-TOO: Results of the HOPE Study Extension.

VBWG HOPE-TOO: Results of the HOPE Study Extension.
Norwegian Vitamin Trial NORVITNORVIT Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Kaare Harold Bønaa.

Norwegian Vitamin Trial NORVITNORVIT Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Kaare Harold Bønaa.
ALLHAT 6/5/2006 - 1 CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
NSTE Acute Coronary Syndromes

NSTE Acute Coronary Syndromes
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
CAPRICORN Adverse CV Events (Frequency ≥ 1.5%) in Either Treatment Group (Uptitration Phase)

CAPRICORN Adverse CV Events (Frequency ≥ 1.5%) in Either Treatment Group (Uptitration Phase)

Similar presentations

Ads by Google